BAP1 Loss Affords Lipotoxicity Resistance in Uveal Melanoma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.BAP1-deficient uveal melanoma (UM) cells resist lipid toxicity, unlike BAP1-competent cells. This resistance, linked to ASXL2, offers new therapeutic targets for metastatic UM liver spread.
Area Of Science
- Oncology
- Molecular Biology
- Metabolic Research
Background
- Uveal melanoma (UM) is an aggressive eye cancer with high metastatic potential, predominantly to the liver.
- BAP1 deficiency is common in metastatic UM and linked to poor prognosis.
- BAP1 loss may enhance fatty acid processing and lipid tolerance in UM cells.
Purpose Of The Study
- To investigate the role of BAP1 in UM cell adaptation to the hepatic microenvironment.
- To explore the link between BAP1, lipid metabolism, and ferroptosis in UM.
- To identify therapeutic strategies targeting lipid metabolism in metastatic UM.
Main Methods
- In silico analysis of UM patient samples.
- In vitro experiments assessing lipotoxicity and ferroptosis in BAP1-mutant and BAP1-competent UM cells.
- Ex vivo liver slice model to evaluate atorvastatin efficacy.
- ASXL2 depletion experiments in UM cells.
Main Results
- BAP1-mutant UM cells exhibit resistance to lipotoxicity, while BAP1-competent cells are sensitive, showing ferroptosis-like stress.
- Atorvastatin treatment reduced BAP1-mutant UM tumor burden in a liver slice model.
- ASXL2 depletion in BAP1-competent UM cells conferred lipotoxicity resistance, potentially via PPAR modulation.
Conclusions
- BAP1 deficiency promotes UM cell survival in the liver by enhancing lipid tolerance.
- ASXL2 acts as a mediator linking BAP1 status to lipid sensitivity in UM.
- Targeting lipid metabolism presents a potential therapeutic strategy for metastatic uveal melanoma.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
